Cargando…
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway
Despite the proven clinical antineoplastic activity of histone deacetylase inhibitors (HDACI), their effect has been reported to be lower than expected in B-cell lymphomas. Traditionally considered as “epigenetic drugs”, HDACI modify the acetylation status of an extensive proteome, acting as general...
Autores principales: | Pera, Benet, Krumsiek, Jan, Assouline, Sarit E., Marullo, Rossella, Patel, Jayeshkumar, Phillip, Jude M., Román, Lidia, Mann, Koren K., Cerchietti, Leandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835559/ https://www.ncbi.nlm.nih.gov/pubmed/29396295 http://dx.doi.org/10.1016/j.ebiom.2018.01.014 |
Ejemplares similares
-
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
por: Pera, Benet, et al.
Publicado: (2016) -
Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017) -
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
por: Calvo-Vidal, M. Nieves, et al.
Publicado: (2021) -
Variational autoencoders learn transferrable representations of metabolomics data
por: Gomari, Daniel P., et al.
Publicado: (2022) -
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017)